ClinicalTrials.gg
RecruitingNCT07325214SonoPANIIIUpdated Nov 9, 2026

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

An interventional study of IMD10 and chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] in Pancreatic Cancer, Borderline Resectable Pancreatic Cancer and Locally Advanced Pancreatic Cancer, sponsored by IMGT Co., Ltd.. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by IMGT Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
95th of 1,573
366 · median 37
Started
2026
with 82 others
No phase
246 of 1,850
49 open now
Primary completion
2030-01
later than 415 of 468 live
Registered
1,778th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 95th largest by planned enrollment of the 1,573 interventional ones that give a count, is one of 83 that started in 2026, is one of 246 with no phase, reaches primary completion later than 415 of the 468 other live ones, and was the 1,778th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

291 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.

Read the detailed description
  • Background: Pancreatic Cancer (PaC) ranks as the 5th most common cause of cancer-related deaths in the Western world. Despite medical advances, PaC continues to have a dismal 5-year survival rate of only 8%. Since the pancreas is in the retroperitoneal cavity, there are few specific symptoms in the early stages, and cancer tissue grows relatively quickly, meaning it is often already advanced at the time of diagnosis.
  • Study Design: This is a multinational, randomized, pivotal clinical trial conducted at multiple sites in the United States and the Republic of Korea. Eligible participants will be randomized in a 1:1 ratio to experimental group or control group.
  • Interventions: Participants in the experimental group will receive chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] with IMD10.

Participants in the control group will receive chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] alone.

  • Outcome Measures: The primary outcome measure is overall survival. Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. For participants still alive at the time of analysis, the OS time is censored on the last date the participants were known to be alive.
  • Follow-up: Participants will be followed for safety and survival until the end of study.
03

Conditions studied

  • Pancreatic Cancer
  • Borderline Resectable Pancreatic Cancer
  • Locally Advanced Pancreatic Cancer

Keywords

  • Focused Ultrasound
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

An individual must meet all the following criteria:

-1. Willing and able to understand and sign an ICF and to comply with all aspects of the protocol

  • 2. Aged between 18 and 85 years, inclusive
  • 3. Histologically or cytologically, confirmed diagnosis of PDAC.
  • 4. Classification as BRPC or LAPC according to the NCCN Guidelines (The latest Edition) by radiologic test (CT or MRI), eligible for chemotherapy regimen within 4 weeks of the screening visit
  • 5. Must have at least 1 per 1.1 criteria at the screening visit.
  • 6. The performance status 0 or 1
  • 7. Trial participant having laboratory values defined as:

    -- ≥ 1.5 x 109/L

    • count ≥ 100 x 109/L
    • and ALT ≤ 2.5 x
    • Serum creatinine ≤ 1.5 x ULN
  • 8. is more than 12 weeks
  • 9. A female is eligible to trial participate if not pregnant, not breast feeding -and either a woman not of or, if a woman of childbearing potential agrees to use highly effective methods of from screening to EOS
  • 10. A male trial participant with female partner(s) of childbearing potential agrees to use highly effective methods of contraception from screening to EOS

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participating in this clinical trial:

  • 1. The presence of a cystic lesion within tumor to be treated, or at the pancreas adjacent to the treated tumor.
  • 2. Extensive scars or surgical clips observed in the region through which the ultrasound beam will pass
  • 3. Targeted tumor(s) is not clearly visible with IMD10.
  • 4. Tumor is not treatable by the working range of IMD10
  • 5. Patient has difficulty in lying in supine position.
  • 6. Known history of severe to ultrasound gel or to chemotherapies (irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin) used in this clinical trial
  • 7. Known, or ongoing receipt at the time of screening, of anti-tumor therapy for pancreatic cancer including chemotherapy, radiation, and/or surgery
  • 8. A cardiovascular condition at the time of the screening visit that deems trial participation inappropriate due to one or more of the following:

    • Class III or IV heart failure according to (NYHA) classification

      • Acute coronary syndrome (unstable angina or myocardial infarction) within the last 24 weeks --③ Uncontrolled heart arrhythmia

        • Other cardiovascular abnormalities as determined by the investigator
  • 9. Known history at the time of the screening visit that deems trial participation inappropriate due to one or more of the following:

    • Other uncontrolled chronic infectious diseases

      • Active disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing spondylitis, etc.)

        • Congenital or acquired immunodeficiency diseases, such as cellular immunodeficiency, hypogammaglobulinemia, and hypergammaglobulinemia.

          • Clinically significant mental illness
  • 10. Known history of other than pancreatic cancer within the last 2 years
  • 11. Known history of major surgery within 4 weeks of the cycle 1 day 1 (C1D1)
  • 12. Pregnant and breastfeeding women
  • 13. Participating in another drug/device clinical trial or have participated in another drug/device clinical trial within 4 weeks of C1D1
  • 14. Trial participation in the clinical trial is deemed inappropriate at the investigator's discretion, either for ethical reasons or due to potential impact on the clinical trial's outcome
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
366 participants (estimated)

Study arms

  • Experimental
    Experimental group

    The experimental group receives IMD10 combined with the chemotherapy regimen \[irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin\].

    Device: IMD10 · Drug: chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]

  • Active comparator
    Control group

    The control group receives the chemotherapy regimen \[irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin\] alone, the same regimen administered to the experimental group.

    Drug: chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]

Interventions

  • DeviceIMD10

    A non-thermal/non-tissue destructive Focused Ultrasound (FUS) device

  • Drugchemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]

    Chemotherapy regimen consisting of irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From the date of the first trial participant's randomization to 24 months after the last trial participant's randomization

07

Study locations

1 of 5 sites recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • Jiping Wang, M.D. · Contact
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
    Not yet recruiting
    • Richard Tuli, M.D. · Contact
  • University of Virginia Medical Center
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Allan Tsung, M.D. · Contact
  • Seoul National University Bundang Hospital,
    Gyeonggi-do, 13620, South Korea
    Not yet recruiting
    • Jinhyeok Hwang, M.D. · Contact
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Not yet recruiting
    • Jaeyoung Lee, M.D. · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jan 2030, 38 months after the start.

Of 432 interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 38 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 8, 2026
StartActual
Nov 4, 2026was Sep 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
Show 5 sites
  • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
  • University of Texas Health Science Center at San Antonio · San Antonio, United Statesno status→Not yet recruiting
  • University of Virginia Medical Center · Charlottesville, United Statesno status→Recruiting
  • Seoul National University Bundang Hospital, · Gyeonggi-do, South Koreano status→Not yet recruiting
  • Seoul National University Hospital · Seoul, South Koreano status→Not yet recruiting
Nov 9, 2026
Start date
Sep 2026→Nov 4, 2026 (actual)
Nov 9, 2026
Enrollment
360→366
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
    Show 5 sites
    • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
    • University of Texas Health Science Center at San Antonio · San Antonio, United Statesno status→Not yet recruiting
    • University of Virginia Medical Center · Charlottesville, United Statesno status→Recruiting
    • Seoul National University Bundang Hospital, · Gyeonggi-do, South Koreano status→Not yet recruiting
    • Seoul National University Hospital · Seoul, South Koreano status→Not yet recruiting
    Start date Sep 2026→Nov 4, 2026 (now actual)
    Enrollment 360→366
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07325214
Lead sponsor
IMGT Co., Ltd.
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Nov 4, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Jeongmin Jang
Contact
jeongmin.jang@nanoimgt.com
+82-70-5080-2438

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion